Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era”

NodeGuardian · 2026-03-25T20:17:36+00:00

Jim Cramer advised caution on ImmunityBio (IBRX), labeling it as part of the "magical thinking era." He suggested investors take profits after recent gains and explore other AI stocks with better potential and lower risk.

NodeGuardian

2026-03-25 20:17:36

Abstract generation in progress

Jim Cramer commented on ImmunityBio (NASDAQ: IBRX), calling it part of the “magical thinking era” and advising caution due to its significant recent run. He suggested that investors should consider taking profits after its large gains following an FDA meeting. The article also recommends exploring other AI stocks with greater upside potential and less risk.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.